Patient - PACT
New Clinical Trial and Research

Trial title	Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis
Trial synopsis	The main purpose of this study is to see how GLPG1690 works together with the current standard treatment on your lung function and IPF disease in general. The study will also investigate how well GLPG1690 is tolerated (for example if you get any side effects while on study drug).
Investigational medicinal product, comparator and randomisation	Active dose A GLPG1690 / oral; Active dose B GLPG1690/oral; Matching placebo / oral; 1:1:1
Disease target	Idiopathic Pulmonary Fibrosis
Sponsor	Galapagos NV
Duration	4 weeks of screening followed by at least 52 weeks of treatment and 1 month follow up.
Trial Status	Recruiting
Lead site(s) in Australia	Lung Research Qld Royal Adelaide Hospital, SA
Lead site(s) in New Zealand	Christchurch Hospital, Christchurch
Additional sites	Flinders Medical Centre SA, Respiratory Clinical Trials Pty Ltd SA, St Vincent's Hospital NSW, Royal Prince Alfred Hospital NSW, Concord Repatriation General Hospital NSW, Austin Health VIC, The Alfred Hospital VIC, Box Hill Hospital VIC, Greenlane Clinical Centre Auckland, NZ Respiratory & Sleep Institute Auckland, Waikato Hospital Hamilton
Contact	pactcoordinator@cre-pf.org.au